CML Piramid: CML Pediatric ITK Response According to Molecular Identification at Diagnosis

Sponsor
University Hospital, Bordeaux (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05605379
Collaborator
(none)
88
13

Study Details

Study Description

Brief Summary

Treatment of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitor (TKI). Nevertheless, case of failure and suboptimal response are still observed even in children. Pediatric CML is a rare disease and differs from adult in terms of disease presentation and treatment response underlying a likely different CML biology. Molecular mechanisms that induce resistance to TKI are still poorly characterized except mutations in the tyrosine kinase domain of BCR::ABL1. We propose to search for a molecular signature to predict the response to TKI in the pediatric population.

Condition or Disease Intervention/Treatment Phase
  • Biological: Next Generation Sequencing (DNA and RNA)

Detailed Description

Commonly mutated genes associated with myeloid malignancies have been described in acceleration phase and blastic phase but also at diagnostic in adult chronic phase-CML (CP-CML). The impact of these mutations on treatment response is still debated but several studies observed a worse outcome in adult patients with some mutations. In children only one study explored the molecular status of 30 genes in 21 children and young adults. They found a higher proportion of ASXL1 mutations in children than in adult They did not observed any significant difference in overall survival of ASXL1 mutated versus non-mutated patients but probably due the small size of the cohort. We propose here, to investigate retrospectively on DNA at diagnosis of 88 CP-CML children the mutation status of 64 genes by next generation sequencing and to see if there is an association with the response to TKI treatment. We will complete the molecular signature by analyzing the differentially genetic expression profile by RNA-seq on peripheral blood RNA of 8 patients with CCR at 12 months (and/or a BCR ::ABL1 IS ≤1%IS) and 8 patients with no CCR at 12 months.

Study Design

Study Type:
Observational
Anticipated Enrollment :
88 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
CML Pediatric ITK Response According to Molecular Identification at Diagnosis (CML Piramid
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Responders (with CCR at 1 year)

Biological: Next Generation Sequencing (DNA and RNA)
Targeted Next Generation Sequencing (DNA and RNA)

No responders (without CCR at 1 year)

Biological: Next Generation Sequencing (DNA and RNA)
Targeted Next Generation Sequencing (DNA and RNA)

Outcome Measures

Primary Outcome Measures

  1. Complete cytogenetic response (CCR) [At 12 months from TKI start]

    We will analyse the impact of the presence of mutations on the obtention of CCR

Secondary Outcome Measures

  1. Molecular response [At 3, 12, 18 and 24 months]

    We will analyse the impact of the presence of mutations on the obtention of molecular response (MR4, MMR)

  2. Type of response according to ELN2020 criteria [At 3, 12, 18 and 24 months]

    We will analyse the impact of the presence of mutations on the type of response

  3. Occurrence of secondary resistance [At 3, 12, 18 and 24 months]

    We will analyse the impact of the presence of mutations on the occurrence of loss of complete hematologic, and/or cytogenetic and/or molecular responses

  4. Occurrence of TK domain mutation [At 3, 12 18 and 24 months]

    We will analyse the impact of the presence of mutations on the occurrence of mutation in the TK domain ABL1

  5. Progression Free Survival (PFS) [At 3, 12, 18 and 24 months]

    Progression to accelerated phase or blast crisis and deaths will be analysis according to the mutational status

  6. Overall Survival (OS) [At 3, 12, 18 and 24 months]

    We will analyse the impact of the presence of mutations on OS

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age at diagnosis less than or equal to 18 years

  • Presence of a Philadelphia chromosome detected by cytogenetic analysis (conventional karyotype or Fluorescence In Situ Hybridization (FISH)) and a BCR ::ABL1 transcript e13a2 ou e14a2

  • Diagnosis in chronic phase according to the European Leukemia Net (ELN) criteria

  • First-line treatment with TKIs

  • Possible pre-treatment with hydroxyurea

  • DNA available at diagnosis

  • RNA available for a sub-group patients (8 responders vs 8 no responders)

Exclusion Criteria:
  • Age at diagnosis more than 18 years

  • Diagnosis in accelerated phase or blastic phase

  • First line treatment other than TKI

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Bordeaux

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT05605379
Other Study ID Numbers:
  • CHUBX 2022/44
First Posted:
Nov 4, 2022
Last Update Posted:
Nov 4, 2022
Last Verified:
Oct 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Bordeaux
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 4, 2022